Ani Pharmaceuticals (ANIP) Total Current Liabilities (2010 - 2026)

Ani Pharmaceuticals (ANIP) has 17 years of Total Current Liabilities data on file, last reported at $239.5 million in Q1 2026.

• For the quarter ending Q1 2026, Total Current Liabilities rose 18.68% year-over-year to $239.5 million; the trailing twelve-month figure through Mar 2026 stood at $239.5 million (up 18.68% YoY), and the FY2025 full-year result was $278.1 million, up 43.02% from the prior year.
• Total Current Liabilities eased to $239.5 million in Q1 2026, from $278.1 million in the prior quarter.
• In the past five years, Total Current Liabilities ranged from a high of $278.1 million in Q4 2025 to a low of $79.5 million in Q1 2022.
• A 5-year average of $163.1 million and a median of $140.0 million in 2024 frame the typical range for Total Current Liabilities.
• Across the five-year window, Total Current Liabilities declined 3.91% in 2022 and surged 69.19% in 2025, its largest moves.
• Tracing ANIP's Total Current Liabilities over 5 years: stood at $99.4 million in 2022, then surged by 46.3% to $145.5 million in 2023, then jumped by 33.67% to $194.5 million in 2024, then surged by 43.02% to $278.1 million in 2025, then fell by 13.88% to $239.5 million in 2026.
• Business Quant data shows ANIP's Total Current Liabilities at $239.5 million in Q1 2026, $278.1 million in Q4 2025, and $270.6 million in Q3 2025.